Economic Atlas
Companies/Puma Biotechnology, Inc.
Company profile

Puma Biotechnology, Inc.

NASDAQ: PBYI · Healthcare · Biotechnology
PublicHQ Los Angeles, CA · Los AngelesCIK 0001401667Reports USD
#283 of 1,422 Healthcare companies by revenue39th-percentile growth
EA Score
72B
Revenue TTM
$227.2M
Rev growth YoY (TTM)
-2.4%
Net income (FY)
$31.1M
Employees
179
as of 2026-08-12
Market cap
$446.4M
as of 2026-08-12

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$228.4M$228.4M2025
Net income$31.1M$31.1M2025
Operating income$37.3M$37.3M2025
Total assets$216.3M$216.3M2025
Liabilities$86.0M$86.0M2025
Equity$130.3M$130.3M2025

Revenue trend

FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
Product89%
Royalty11%
By geography

Not disclosed.

The read

What is Puma Biotechnology, Inc.’s revenue?

Puma Biotechnology, Inc. booked $228.4M in FY2025 revenue, contracting 0.9% year over year — slower than 61% of Healthcare companies we track, at a 13.6% net margin.

Peers · Healthcare
AnaptysBio, Inc.75B+Cerus Corporation74BTalkspace, Inc.71BAxoGen, Inc.80B+IDEAYA Biosciences, Inc.67BVanda Pharmaceuticals Inc.63C
Neighbors
Los Angeles →
The Walt Disney Company$94.4B72BPublic Storage$4.8B80B+Southern California Gas Company PFD SER A 6%——Ares Management Corporation$5.6B68BLive Nation Entertainment, Inc.$25.2B76B+Rocket Lab USA, Inc.$601.8M50D
Key facts
CEOAlan H. Auerbach
SectorHealthcare
IndustryBiotechnology
HeadquartersLos Angeles, CA
ExchangeNASDAQ: PBYI
Employees179
IPO date2012-04-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.